Approximately 4 percent of the more than 10 million new cases of TB diagnosed each year are resistant to at least two drugs, and 10 percent of those are “extensively drug-resistant” to multiple medications. Traditional drug resistance tests are often unable to detect all resistance-conferring genetic mutations and can take several weeks, during which time the disease can continue to develop resistance to even more antibiotics.
Researchers from Boston-based Harvard Medical School’s department of biomedical informatics developed the new program, which predicts a TB strain’s resistance to 10 different antibiotics in a tenth of a second, takes a wider variety of genetic mutations into account and shows greater precision than other models. The program will soon be added to the school’s online resource for the analysis of TB genomic data, genTB.
More articles about AI:
AI-powered kidney disease diagnostic tool receives FDA ‘Breakthrough Device’ designation
Novartis, Pfizer, Centene CEOs on AI’s limitations in healthcare
FDA exploring use of AI, blockchain to monitor food safety
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
